A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

NCT02361086 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-resistant Prostate Cancer
CRPC

Interventions

DRUG: VT-464: given orally once daily in 28 day cycles

Sponsor

Innocrin Pharmaceutical